Neuronopathy, distal hereditary motor, autosomal dominant 15
disease diseaseOn this page
Summary
Neuronopathy, distal hereditary motor, autosomal dominant 15 (MONDO:0976226) is a disease with 1 cohort gene.
At a glance
- Cohort genes: 1
- ClinVar variants: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | neuronopathy, distal hereditary motor, autosomal dominant 15 |
| Mondo ID | MONDO:0976226 |
| OMIM | 621094 |
| DOID | DOID:0051042 |
| UMLS | C5975628 |
| MedGen | 1875158 |
| GARD | 0027432 |
| Is cancer (heuristic) | no |
Data availability: 1 ClinVar variant.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal dominant disease › neuronopathy, distal hereditary motor, autosomal dominant › neuronopathy, distal hereditary motor, autosomal dominant 15
Related subtypes (10): neuronopathy, distal hereditary motor, autosomal dominant 1, hereditary spastic paraplegia 17, neuronopathy, distal hereditary motor, autosomal dominant 8, distal hereditary motor neuropathy type 2, distal hereditary motor neuropathy type 7, neuronopathy, distal hereditary motor, type 9, neuronopathy, distal hereditary motor, type 5, neuronopathy, distal hereditary motor, autosomal dominant 10, neuronopathy, distal hereditary motor, autosomal dominant 11, myopathy, myofibrillar, 13, with rimmed vacuoles
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
1 retrieved; paginated sample, class counts are floors:
1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 3603262 | NM_004281.4(BAG3):c.1513_1514insGGAC (p.Val505fs) | BAG3 | Pathogenic | no assertion criteria provided |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| BAG3 | Orphanet:154 | Familial isolated dilated cardiomyopathy |
| BAG3 | Orphanet:199340 | BAG3-related myofibrillar myopathy |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| BAG3 | HGNC:939 | ENSG00000151929 | O95817 | BAG family molecular chaperone regulator 3 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| BAG3 | BAG family molecular chaperone regulator 3 | Co-chaperone and adapter protein that connects different classes of molecular chaperones including heat shock proteins 70 (HSP70s), e.g. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Scaffold/PPI | 1 | 17.3× | 0.058 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| BAG3 | Scaffold/PPI | no | WW_dom, BAG_domain, WW_dom_sf |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| body of tongue | 1 |
| gastrocnemius | 1 |
| skeletal muscle tissue of rectus abdominis | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| BAG3 | 286 | ubiquitous | marker | gastrocnemius, skeletal muscle tissue of rectus abdominis, body of tongue |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| BAG3 | 4,957 |
Structural data
PDB: 0 · AlphaFold-only: 1 · No structure: 0
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| BAG3 | O95817 | 57.98 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 4. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Cellular response to heat stress | 1 | 393.8× | 0.010 | BAG3 |
| Regulation of HSF1-mediated heat shock response | 1 | 139.3× | 0.014 | BAG3 |
| Cellular responses to stress | 1 | 36.8× | 0.032 | BAG3 |
| Cellular responses to stimuli | 1 | 31.5× | 0.032 | BAG3 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| striated muscle cell apoptotic process | 1 | 16852.0× | 0.001 | BAG3 |
| negative regulation of striated muscle cell apoptotic process | 1 | 5617.3× | 0.001 | BAG3 |
| protein transport along microtubule | 1 | 5617.3× | 0.001 | BAG3 |
| chaperone-mediated autophagy | 1 | 2808.7× | 0.001 | BAG3 |
| aggresome assembly | 1 | 2808.7× | 0.001 | BAG3 |
| obsolete negative regulation of protein targeting to mitochondrion | 1 | 2808.7× | 0.001 | BAG3 |
| positive regulation of aggrephagy | 1 | 2808.7× | 0.001 | BAG3 |
| cellular response to unfolded protein | 1 | 991.3× | 0.003 | BAG3 |
| positive regulation of protein export from nucleus | 1 | 802.5× | 0.003 | BAG3 |
| muscle cell cellular homeostasis | 1 | 648.1× | 0.003 | BAG3 |
| spinal cord development | 1 | 510.7× | 0.004 | BAG3 |
| extrinsic apoptotic signaling pathway in absence of ligand | 1 | 468.1× | 0.004 | BAG3 |
| positive regulation of protein import into nucleus | 1 | 421.3× | 0.004 | BAG3 |
| extrinsic apoptotic signaling pathway via death domain receptors | 1 | 401.2× | 0.004 | BAG3 |
| cellular response to heat | 1 | 343.9× | 0.004 | BAG3 |
| autophagosome assembly | 1 | 224.7× | 0.005 | BAG3 |
| cellular response to mechanical stimulus | 1 | 216.1× | 0.005 | BAG3 |
| protein folding | 1 | 103.4× | 0.011 | BAG3 |
| protein stabilization | 1 | 66.9× | 0.016 | BAG3 |
| negative regulation of apoptotic process | 1 | 34.8× | 0.029 | BAG3 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| BAG3 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| BAG3 | 8 | Binding:8 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | BAG3 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| BAG3 | 8 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: BAG3